Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring

Journal of Cystic Fibrosis

Volumn 12, Issue 4, 2013, Pages 403-406

  Stenbit, Antine E ^a   Bullington, Wendy M ^b   Heh, Julie L ^b   Flume, Patrick A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cystic fibrosis; Inhaled tobramycin; TOBI; Tobramycin levels

Indexed keywords

COTRIMOXAZOLE; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG MONITORING; FEMALE; HUMANS; MALE; TOBRAMYCIN; VEINS; YOUNG ADULT;

EID: 84878355967     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.11.007     Document Type: Article

References (11)

1. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176(10):957-969. [Epub 2007/09/01].
2. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180(9):802-808. [Epub 2009/09/05].
3. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122(1):219-226. [Epub 2002/07/13].
4. Geller D.E., Rosenfeld M., Waltz D.A., Wilmott R.W. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003, 123(1):28-36. [Epub 2003/01/16].
5. Touw D.J., Jacobs F.A., Brimicombe R.W., Heijerman H.G., Bakker W., Briemer D.D. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997, 41(1):184-187. [Epub 1997/01/01].
6. McRorie T.I., Bosso J., Randolph L. Aminoglycoside ototoxicity in cystic fibrosis: evaluation by high-frequency audiometry. Am J Dis Child 1989, 143(11):1328-1332.
7. Mingeot-Leclercq M.-P., Tulkens P.M. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999, 43(5):1003-1012.
8. Scott C.S., Retsch-Bogart G.Z., Henry M.M. Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen. Pediatr Pulmonol 2001, 31(4):314-316. [Epub 2001/04/05].
9. Elidemir O., Maciejewski S.R., Oermann C.M., et al. Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin. Pediatr Pulmonol 2000, 29(1):43-45. [Epub 1999/12/29].
10. Redmann S., Wainwright C., Stacey S., Champion A., Mitchell P., Cheney J., et al. Misleading high tobramycin plasma concentrations can be caused by skin contamination of fingerprick blood following inhalation of nebulized tobramycin (TOBI): a short report. Ther Drug Monit 2005, 27(2):205-207. [Epub 2005/03/30].
11. MacArthur R.D., Lolans V., Zar F.A., Jackson G.G. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis 1984, 150(5):778-779. [Epub 1984/11/01].